Abstract
The specificity of two cyclosporin immunoassays were evaluated. Eleven patients were followed for the first four weeks after heart ( n = 3) or liver ( n = 8) transplantation. Cyclosporin A (CsA) monitoring was performed concomitantly by a monoclonal fluorescence polarization immunoassay (mFPIA) and enzyme-multiplied immunoassay technique (EMIT ®) during this period. For several patients, cyclosporin monitoring was also performed by high performance liquid chromatography (HPLC) or by polyclonal fluorescence polarization immunoassay (pFPIA). Liver function was assessed by follow-up of plasma total bilirubin, γ-glutamyl transferase and alkaline phosphatase and renal function by plasma creatinine. All the patients presented episodes of impaired liver function. Higher CsA levels were found using mFPIA measurements as compared to the EMIT ® measurements (ratio mFPIA:EMIT ® (medium range) = 1.4 (1.0–2.3)). A higher degree of cross-reactivity of the antibody used in the mFPIA as compared to the EMIT ® was demonstrated by specific measurements of CsA and its primary metabolite, AMl, by HPLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
